Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 1994 Nov;31(11):843–847. doi: 10.1136/jmg.31.11.843

Deletions in the 5' region of dystrophin and resulting phenotypes.

F Muntoni 1, P Gobbi 1, C Sewry 1, T Sherratt 1, J Taylor 1, S K Sandhu 1, S Abbs 1, R Roberts 1, S V Hodgson 1, M Bobrow 1, et al.
PMCID: PMC1016656  PMID: 7853367

Abstract

Deletions in the dystrophin gene give rise to both Duchenne and Becker muscular dystrophies. Good correlation is generally found between the severity of the phenotype and the effect of the deletion on the reading frame: deletions that disrupt the reading frame result in a severe phenotype, while in frame deletions are associated with a milder disease course. Rare exceptions to this rule, mainly owing to frameshift mutations in the 5' region of the gene (in particular deletions involving exons 3 to 7) which are associated with a milder than expected phenotype, have been reported previously. In order to characterise better the relationship between genotype and phenotype as a result of mutations arising in the 5' region of the gene, we have studied a large cohort of patients with small in frame and out of frame deletions in the first 13 exons of the dystrophin gene. Fifty-five patients with a deletion in this area were identified; approximately one third of them had a phenotype different from that theoretically expected. Patients were divided into two groups: (1) patients with a severe clinical phenotype despite the presence of a small, in frame deletion and (2) patients with a mild phenotype and an out of frame deletion. Noticeable examples observed in the first group were Duchenne boys with a deletion of exon 5, of exon 3, and of exons 3-13. In the second group we observed several patients with an intermediate or Becker phenotype and out of frame deletions involving not only the usual exons 3-7 but also 5-7 and 3-6. These data indicate that a high proportion of patients with a deletion in the 5' end of the gene have a phenotype that is not predictable on the basis of the effect of the deletion on the reading frame. The N-terminus of dystrophin has at least one actin binding domain that might be affected by the small, in frame deletions in this area. The effect of the in frame deletions of exon 3, 5, and 3-13 on this domain might account for the severe phenotype observed in these patients. Other mechanisms, such as unexpected effect of the deletion on splicing behaviour, might, however, also be implicated in determining the phenotype outcome.

Full text

PDF
843

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arahata K., Beggs A. H., Honda H., Ito S., Ishiura S., Tsukahara T., Ishiguro T., Eguchi C., Orimo S., Arikawa E. Preservation of the C-terminus of dystrophin molecule in the skeletal muscle from Becker muscular dystrophy. J Neurol Sci. 1991 Feb;101(2):148–156. doi: 10.1016/0022-510x(91)90039-a. [DOI] [PubMed] [Google Scholar]
  2. Beggs A. H., Hoffman E. P., Snyder J. R., Arahata K., Specht L., Shapiro F., Angelini C., Sugita H., Kunkel L. M. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet. 1991 Jul;49(1):54–67. [PMC free article] [PubMed] [Google Scholar]
  3. Beggs A. H., Koenig M., Boyce F. M., Kunkel L. M. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum Genet. 1990 Nov;86(1):45–48. doi: 10.1007/BF00205170. [DOI] [PubMed] [Google Scholar]
  4. Bulman D. E., Murphy E. G., Zubrzycka-Gaarn E. E., Worton R. G., Ray P. N. Differentiation of Duchenne and Becker muscular dystrophy phenotypes with amino- and carboxy-terminal antisera specific for dystrophin. Am J Hum Genet. 1991 Feb;48(2):295–304. [PMC free article] [PubMed] [Google Scholar]
  5. Chelly J., Gilgenkrantz H., Lambert M., Hamard G., Chafey P., Récan D., Katz P., de la Chapelle A., Koenig M., Ginjaar I. B. Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies. Cell. 1990 Dec 21;63(6):1239–1248. doi: 10.1016/0092-8674(90)90419-f. [DOI] [PubMed] [Google Scholar]
  6. Clerk A., Strong P. N., Sewry C. A. Characterisation of dystrophin during development of human skeletal muscle. Development. 1992 Feb;114(2):395–402. doi: 10.1242/dev.114.2.395. [DOI] [PubMed] [Google Scholar]
  7. Gangopadhyay S. B., Sherratt T. G., Heckmatt J. Z., Dubowitz V., Miller G., Shokeir M., Ray P. N., Strong P. N., Worton R. G. Dystrophin in frameshift deletion patients with Becker muscular dystrophy. Am J Hum Genet. 1992 Sep;51(3):562–570. [PMC free article] [PubMed] [Google Scholar]
  8. Gillard E. F., Chamberlain J. S., Murphy E. G., Duff C. L., Smith B., Burghes A. H., Thompson M. W., Sutherland J., Oss I., Bodrug S. E. Molecular and phenotypic analysis of patients with deletions within the deletion-rich region of the Duchenne muscular dystrophy (DMD) gene. Am J Hum Genet. 1989 Oct;45(4):507–520. [PMC free article] [PubMed] [Google Scholar]
  9. Hodgson S. V., Abbs S., Clark S., Manzur A., Heckmatt J. Z., Dubowitz V., Bobrow M. Correlation of clinical and deletion data in Duchenne and Becker muscular dystrophy, with special reference to mental ability. Neuromuscul Disord. 1992;2(4):269–276. doi: 10.1016/0960-8966(92)90059-f. [DOI] [PubMed] [Google Scholar]
  10. Koenig M., Beggs A. H., Moyer M., Scherpf S., Heindrich K., Bettecken T., Meng G., Müller C. R., Lindlöf M., Kaariainen H. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 1989 Oct;45(4):498–506. [PMC free article] [PubMed] [Google Scholar]
  11. Koenig M., Hoffman E. P., Bertelson C. J., Monaco A. P., Feener C., Kunkel L. M. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987 Jul 31;50(3):509–517. doi: 10.1016/0092-8674(87)90504-6. [DOI] [PubMed] [Google Scholar]
  12. Le T. T., Nguyen T. M., Love D. R., Helliwell T. R., Davies K. E., Morris G. E. Monoclonal antibodies against the muscle-specific N-terminus of dystrophin: characterization of dystrophin in a muscular dystrophy patient with a frameshift deletion of exons 3-7. Am J Hum Genet. 1993 Jul;53(1):131–139. [PMC free article] [PubMed] [Google Scholar]
  13. Levine B. A., Moir A. J., Patchell V. B., Perry S. V. The interaction of actin with dystrophin. FEBS Lett. 1990 Apr 9;263(1):159–162. doi: 10.1016/0014-5793(90)80728-2. [DOI] [PubMed] [Google Scholar]
  14. Malhotra S. B., Hart K. A., Klamut H. J., Thomas N. S., Bodrug S. E., Burghes A. H., Bobrow M., Harper P. S., Thompson M. W., Ray P. N. Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science. 1988 Nov 4;242(4879):755–759. doi: 10.1126/science.3055295. [DOI] [PubMed] [Google Scholar]
  15. Monaco A. P., Neve R. L., Colletti-Feener C., Bertelson C. J., Kurnit D. M., Kunkel L. M. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature. 1986 Oct 16;323(6089):646–650. doi: 10.1038/323646a0. [DOI] [PubMed] [Google Scholar]
  16. Muntoni F., Mateddu A., Cianchetti C., Marrosu M. G., Clerk A., Cau M., Congiu R., Cao A., Melis M. A. Dystrophin analysis using a panel of anti-dystrophin antibodies in Duchenne and Becker muscular dystrophy. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):26–31. doi: 10.1136/jnnp.56.1.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nicholson L. V., Davison K., Falkous G., Harwood C., O'Donnell E., Slater C. R., Harris J. B. Dystrophin in skeletal muscle. I. Western blot analysis using a monoclonal antibody. J Neurol Sci. 1989 Dec;94(1-3):125–136. doi: 10.1016/0022-510x(89)90223-2. [DOI] [PubMed] [Google Scholar]
  18. Nicholson L. V., Johnson M. A., Bushby K. M., Gardner-Medwin D., Curtis A., Ginjaar I. B., den Dunnen J. T., Welch J. L., Butler T. J., Bakker E. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups. J Med Genet. 1993 Sep;30(9):728–736. doi: 10.1136/jmg.30.9.728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nicholson L. V., Johnson M. A., Davison K., O'Donnell E., Falkous G., Barron M., Harris J. B. Dystrophin or a "related protein" in Duchenne muscular dystrophy? Acta Neurol Scand. 1992 Jul;86(1):8–14. doi: 10.1111/j.1600-0404.1992.tb08046.x. [DOI] [PubMed] [Google Scholar]
  20. Prior T. W., Papp A. C., Snyder P. J., Burghes A. H., Bartolo C., Sedra M. S., Western L. M., Mendell J. R. A missense mutation in the dystrophin gene in a Duchenne muscular dystrophy patient. Nat Genet. 1993 Aug;4(4):357–360. doi: 10.1038/ng0893-357. [DOI] [PubMed] [Google Scholar]
  21. Roberts R. G., Gardner R. J., Bobrow M. Searching for the 1 in 2,400,000: a review of dystrophin gene point mutations. Hum Mutat. 1994;4(1):1–11. doi: 10.1002/humu.1380040102. [DOI] [PubMed] [Google Scholar]
  22. Scott O. M., Hyde S. A., Goddard C., Dubowitz V. Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle Nerve. 1982 Apr;5(4):291–301. doi: 10.1002/mus.880050405. [DOI] [PubMed] [Google Scholar]
  23. Sewry C. A., Dubowitz V., Abraha A., Luzio J. P., Campbell A. K. Immunocytochemical localisation of complement components C8 and C9 in human diseased muscle. The role of complement in muscle fibre damage. J Neurol Sci. 1987 Nov;81(2-3):141–153. doi: 10.1016/0022-510x(87)90091-8. [DOI] [PubMed] [Google Scholar]
  24. Sherratt T. G., Vulliamy T., Strong P. N. Evolutionary conservation of the dystrophin central rod domain. Biochem J. 1992 Nov 1;287(Pt 3):755–759. doi: 10.1042/bj2870755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Vainzof M., Takata R. I., Passos-Bueno M. R., Pavanello R. C., Zatz M. Is the maintainance of the C-terminus domain of dystrophin enough to ensure a milder Becker muscular dystrophy phenotype? Hum Mol Genet. 1993 Jan;2(1):39–42. doi: 10.1093/hmg/2.1.39. [DOI] [PubMed] [Google Scholar]
  26. Winnard A. V., Klein C. J., Coovert D. D., Prior T., Papp A., Snyder P., Bulman D. E., Ray P. N., McAndrew P., King W. Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophy. Hum Mol Genet. 1993 Jun;2(6):737–744. doi: 10.1093/hmg/2.6.737. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES